Hasil Pencarian  ::  Simpan CSV :: Kembali

"Latar Belakang: Selama beberapa dekade, cisplatin menjadi kemoterapi paling aktif yang tersedia untuk kanker ovarium. Terlepas dari keunggulan hasilnya, cisplatin juga memiliki beberapa efek samping, salah satunya adalah hepatotoksisitas. Dalam perkembangan kedokteran, curcumin ditemukan memiliki efek hepatoprotektif dalam beberapa penelitian, tetapi ternyata memiliki bioavailabilitas yang rendah. Dengan demikian, nanocurcumin dibuat dan ditemukan untuk meningkatkan bioavailabilitasnya. Meskipun demikian, efek curcumin dan nanocurcumin dalam hepatotoksisitas yang disebabkan oleh terapi cisplatin pada kanker ovarium belum diamati. Penelitian ini bertujuan untuk menguji pengaruh kedua obat tersebut terhadap hepatotoksisitas yang diinduksi oleh cisplatin. Metode: Percobaan in vivo dilakukan pada tikus Wistar betina, dengan berat 150-200 gram, yang diinduksi oleh DMBA untuk mencapai model kanker ovarium. Kemudian, terapi cisplatin (4mg / kgBB / minggu) diberikan secara intraperitoneal pada tikus. Kemudian beberapa tikus juga diberi terapi kombinasi dengan curcumin (100 mg / kgBB / hari) dan nanocurcumin (100 mg / kgBB / hari). Tikus-tikus ini dibagi menjadi beberapa kelompok: tikus sehat, tidak ada pengobatan, terapi cisplatin, terapi cisplatin + curcumin, dan terapi cisplatin + nanocurcumin. Setelah sebulan, sampel darah diambil dan disentrifugasi untuk mendapatkan plasma. Tingkat AST, ALT, dan ALP diukur menggunakan spektrofotometer untuk menggambarkan fungsi hati. Hasilnya dianalisis menggunakan one-way ANOVA untuk ALT dan ALP dan Kruskall-Wallis untuk AST, menggunakan perangkat lunak SPSS24. Hasil: Tidak ada perbedaan statistik yang signifikan antara kelompok dalam AST plasma (p = 0,125), AlT (p = 0,154), dan ALP (p = 0,072). Kesimpulan: Tidak ada perbedaan yang signifikan untuk kurkumin dan nanokurkumin dalam mengurangi efek hepatotoksisitas cisplatin

---

Introduction: For decades, cisplatin has remained the most active chemotherapy available for ovarian cancer. Despite the excellence of the outcome, cisplatin also has severe side effects, one of which is hepatotoxicity. In the development of medicine, curcumin was found to exert a hepatoprotective effect in several studies, but it was found to have low bioavailability. Thus, nanocurcumin was established and discovered to improve its bioavailability. Nonetheless, the effect of curcumin and nanocurcumin in hepatotoxicity caused by cisplatin therapy in ovarian cancer has not been observed. This study aims to examine the effect of both drugs on the cisplatin-induced hepatotoxicity. Method: An in vivo experiment was done on female Wistar rats, weighing from 150-200 grams, which was induced by DMBA to achieve ovarian cancer models. Then, cisplatin therapy (4mg/kgBW/week) was given intraperitoneally to the rats. Then some of the rats were also given combination therapy with curcumin (100 mg/kgBW/day) and nanocurcumin (100 mg/kgBW/day). They were divided into groups of: healthy rats, no treatment, cisplatin therapy, cisplatin+curcumin therapy, and cisplatin+nanocurcumin therapy. After a month, blood sample was taken and centrifuged to obtain plasma. The AST, ALT, and ALP level was measured using spectrophotometer to depict the liver function. The result was analysed using one-way ANOVA for ALT and ALP and Kruskall-Wallis for AST using SPSS24 software. Results: Theres no significant statistical difference between groups in plasma AST (p=0.125), AlT (p=0.154), and ALP (p=0.072). Conclusion: There was no significant differences for both curcumin and nanocurcumin in reducing hepatotoxic effect of cisplatin."

"ABSTRAKBackground Rheumatoid arhtirtis is a chronic autoimmune disease that mainly attacks joints. It may causes joint deformities which leads to lower quality of life of RA patients. RA is treated with metothrexate which inhibiting disease progression. MTX is known for its hepatotoxicity side effect, which is described by an elevation of aspartate aminotransferase and/or alanine aminotransferase beyond the upper normal limit. Factors that may enhance hepatotoxicity are gender, age, cummulative dose of MTX, and duration therapy of MTX. Prevalence of hepatotoxicity caused by MTX therapy in RA patients in Indonesia is still unknown. The objective of this research is to know the proportion of hepatotoxicity and its associations with the factors that may enhance hepatotoxicity caused by MTX therapy in RA patients in RSCM.Method Data about gender, age, cummulative dose and duration therapy of MTX are obtained from 115 RA patients medical records.Result Proportion of hepatotoxicity in RA patients treated with MTX in RSCM is 42.60 percent. Gender, age, cummulative dose and duration therapy of MTX do not significantly enhance hepatotoxicity p>0.05. Conclusion In conclusion gender, age, cummulative dose and duration therapy of MTX do not have association with hepatotoxicity in RA patients treated with MTX."

"Karbon tetraklorida (CCl4) lazim dipakai sebagai penginduksi kerusakan hati sehingga sering digunakan dalam pengujian aktivitas hepatoprotektor suatu zat. Karbon tetraklorida dosis tunggal 0,1; 1,0; dan 10 ml/kg bobot badan diberikan secara intraperitoneal pada tikus jantan, dan diamati kerusakan yang terjadi pada hati dan ginjal. Kerusakan hati ditandai dengan peningkatan kadar enzim alanin transaminase (ALT), aspartat transaminase (AST), alkali fosfatase (ALP), bilirubin total, dan protein total dalam serum. Peningkatan kreatinin serum merupakan indikator gangguan fungsi ginjal. Lebih lanjut juga dilakukan pengamatan terhadap gambaran histopatologi hati dan ginjal. Dibandingkan dengan kontrol, CCl4 dosis 0,1 dan 1,0 ml/kg bobot badan mengakibatkan peningkatan ALT dan penurunan AST, dan pada dosis 10 ml/kg bobot badan kadar kedua enzim tersebut sudah sangat turun (p<0,05). Kadar ALP, bilirubin total, dan protein total semua kelompok tidak berbeda (p>0,05). Karbon tetraklorida dosis 0,1 dan 1,0 ml/kg bobot badan mengakibatkan peningkatan kreatinin, sebaliknya pada dosis 10 ml/kg bobot badan kadar kreatinin sudah sangat turun (p<0,05). Gambaran histopatologi kelompok yang mendapatkan 1,0 dan 10 ml CCl4/kg bobot badan menunjukkan terjadinya steatosis pada sel-sel hati, namun pada glomerulus tidak terlihat adanya perubahan. Karbon tetraklorida menimbulkan kerusakan sebanding dengan dosis yang diinduksikan.

---

The Effects of Carbon Tetrachloride Administration on Liver and Renal Function. Carbon tetrachloride (CCl4) that induces liver damage is widely used in hepatoprotector experiments. Carbon tetrachloride at a single dose 0,1; 1,0; and 10 ml/kg body weight was administrated intraperitoneally in male rats to investigate liver and renal damage. Liver damage was monitored by increased alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), total bilirubin, and serum total protein. Increased serum creatinine is an indicator of renal problem. Futhermore, liver and renal tissues were subjected to histopathological studies. Compared with control, injection of 0,1 and 1,0 ml CCl4/kg body weight increased ALT and decreased AST, and at dose 10 ml/kg body weight both ALT and AST decreased to a greater extent (p<0.05). Alkaline phosphatase, total bilirubin, and total protein were not different in all treatments (p>0.05). Carbon tetrachloride at dose 0,1 and 1,0 ml/kg body weight increased creatinine. However, injection of 10 ml CCl4/kg body weight decreased creatinine (p<0.05). Histopathological studies confirmed the presence of steatosis in hepatic cells at single dose of 1,0 and 10 ml CCl4/kg body weight, with no significant effect in glomerulus. Administration of single dose of CCl4 can induce liver and renal damage that dependent on CCl4 received."

"Pendahuluan: Doxorubicin (DOX), agen kemoterapi yang banyak digunakan, diketahui menyebabkan toksisitas pada organ hati. Metabolisme DOX menghasilkan stress oksidatif yang memicu kerusakan DNA, peroksidasi lipid,, dan deplesi ATP, sehingga berujung pada kematian hepatosit. L-citrulline (CIT), yang terkandung pada semangka dan mentimun, banyak menarik perhatian karena sifat antioksidatifnya. Di tubuh, CIT diubah menjadi NO, yang ditunjukkan mengurangi kerusakan hati dengan melawan radikal bebas, memperbaiki mikrosirkulasi sinusoid hati, dan menghambat infiltrasi neutrophil. Studi ini bertujuan untuk menginvestigasi kemampuan CIT dalam mencegah hepatotoksisitas yang diinduksi oleh DOX.Metode: 20 tikus wistar dirandomisasi untuk mendapatkan DOX (10 mg/kgBB) atau NaCl 0.9%. Kelompok yang diintoksikasi oleh DOX juga dirandomisasi untuk diberikan CIT dosis rendah (300 mg/kgBB), CIT dosis tinggi (600 mg/ kgBB), atau akuadest. CIT diberikan secara oral selama 6 hari, sedangkan DOX diberikan melalui injeksi intraperitoneal hanya pada hari ke 4 & 5. Serum diambil sebagai sampel dan hepatotoksisitas ditentukan melalui level serum dari AST, ALT, dan GGT. Analisa statistik dengan one-way ANOVA dan Tukey’s test dilakukan untuk membandingkan data.Hasil: Pemberian DOX menyebabkan peningkatan semua biomarker serum. Kedua dosis CIT mengurangi elevasi ALT secara signifikan (p-value <0.05 vs DOX group). Hanya CIT dosis tinggi mampu mengurangi elevasi AST secara signifikan (p-value <0.05 vs DOX group). Kedua dosis CIT hanya mengurangi elevasi GGT secara insignifikan (p-value >0.05 vs DOX group)

---

Background: The antineoplastic agent Doxorubicin (DOX) is known for causing liver toxicity. Its metabolism in hepatocytes causes oxidative stress, inducing DNA damage, lipid peroxidation, ATP depletion, and apoptosis. L-citrulline (CIT), commonly found in fruits like watermelon, has piqued interest due to its antixodative properties. In the body, CIT is converted to NO, which has been shown to mitigate hepatic injury by scavenging free radicals, improving hepatic sinusoidal microcirculation, and inhibiting neutrophilic infiltration. This study aims to investigate CIT’s ability to prevent DOX-induced hepatotoxicity.

Method: 20 wistar rats were randomized to receive either DOX (10 mg/kgBW) or NaCl 0.9%. DOX-intoxicated group was further randomized to either receives low-dose CIT (300 mg/kgBW), high-dose CIT (600 mg/kgBW), or aquadest. CIT was given orally for 6 days and DOX via intraperitoneal injection on day 4 and 5. Serum was obtained as sample and hepatotoxicity was assessed via the serum levels of AST, ALT, and GGT. Statistical analysis was done with one-way ANOVA and Tukey’s test.

Results: DOX treatment resulted in elevations of all serum biomarkers. Both dosages of CIT significantly attenuated ALT elevation (p <0.05 vs DOX group). Only high-dose CIT significantly attenuated AST elevation (p <0.05 vs DOX group). Both dosages produced insignificant decrease of GGT elevation (p >0.05 vs DOX group)."

"

Doksorubisin merupakan obat kemoterapi yang efektif. Namun, dalam kerjanya, doksorubisin menghasilkan reactive oxygen species (ROS) yang bersifat hepatotoksik. Moringa oleifera merupakan tumbuhan yang memiliki potensi hepatoproteksi dengan kandungan senyawa fenolik dan flavonoidnya yang merupakan antioksidan dan antiinflamasi. Penelitian ini dilakukan untuk mengetahui efek hepatoproteksi ekstrak daun Moringa oleifera (MO) melalui kadar GGT, bilirubin, dan albumin serum. Ketiga parameter ini merupakan biomarker diagnostik dan keparahan kerusakan hati yang dapat dideteksi pada plasma darah. Penelitian ini menggunakan sampel plasma darah tikus tersimpan. Sebanyak 24 ekor tikus Sprague-Dawley jantan dirandomisasi ke dalam 4 kelompok. Kelompok pertama adalah kontrol (Normal) yang diinjeksi NaCl. Ketiga kelompok lainnya diberikan injeksi doksorubisin 4 mg/kgBB/minggu (Dox) atau doksorubisin 4 mg/kgBB/minggu dan MO-200 mg/kgBB/hari (Dox + MO 200) atau doksorubisin 4 mg/kgBB/minggu dan MO-400 mg/kgBB/hari (Dox + MO 400), selama 4 minggu. Pada akhir minggu keempat, tikus dimatikan, lalu darah diambil, disentrifugasi, dan plasma disimpan. Plasma darah tikus tersebut digunakan di penelitian ini untuk dilakukan analisis kadar GGT, bilirubin, dan albumin. Hasil penelitian menunjukkan bahwa kelompok Dox mengalami kerusakan hati yang ditunjukkan oleh peningkatan kadar bilirubin serum secara signifikan. Kadar GGT serum meningkat dan kadar albumin menurun namun tidak signifikan. Kelompok Dox + MO 200 menunjukkan penurunan kadar bilirubin secara bermakna, dan Dox + MO 400 menunjukkan penurunan kadar GGT secara bermakna, sedangkan kadar albumin tidak menunjukkan perbedaan yang bermakna pada keempat kelompok. Dari hasil tersebut, dapat disimpulkan bahwa ekstrak Moringa oleifera dosis 200 mg/kgBB dan 400 mg/kgBB menunjukkan potensi dalam melindungi hati dari toksisitas doksorubisin.

---

Doxorubicin is an effective chemotherapy drug but can lead to hepatotoxicity due to the generation of ROS. Moringa oleifera, rich in flavonoid and phenolic compounds with antioxidant and anti-inflammatory properties, is a potential hepatoprotective agent. This study aimed to assess the hepatoprotective effects of Moringa oleifera leaf extract (MO) on doxorubicin through GGT, bilirubin, and albumin levels, which serve as diagnostic biomarkers for liver damage. This study utilized stored rat plasma samples. Twenty-four male Sprague-Dawley rats were randomly assigned to four groups. The first group (normal control) received NaCl injections. The other three groups were administered doxorubicin at 4 mg/kgBW/week (Dox) or doxorubicin at 4 mg/kgBW/week along with MO at 200 mg/kgBW/day (Dox+MO-200) or doxorubicin at 4 mg/kgBW/week along with MO at 400 mg/kgBW/day (Dox+MO-400) for four weeks. At the end of the fourth week, the rats were euthanized, blood was collected, centrifuged, and plasma was stored. The rat plasma samples were used for analyzing GGT, bilirubin, and albumin levels in this study. The results showed that the Dox group exhibited liver damage as indicated by a significant increase in serum bilirubin levels. Serum GGT levels increased, and albumin levels decreased, although not significantly. The Dox+MO-200 group showed a significant decrease in bilirubin levels, and the Dox+MO-400 group showed a significant decrease in GGT levels. No significant differences were observed in albumin levels among groups. From these results, it can be concluded that MO at doses of 200 mg/kgBW and 400 mg/kgBW demonstrated potential in mitigating doxorubicin-induced liver damage.

"